PARP Inhibitor Market

1
Global PARP Inhibitor Market is Estimated to
Witness High Growth Owing to Increasing Demand
for Targeted Therapies and Rising Incidence of
Cancer The global PARP inhibitor market is
estimated to be valued at US 887.7 million in
2018 and is expected to exhibit a CAGR of 32.4
over the forecast period, according to a new
report published by Coherent Market Insights.
Market Overview PARP inhibitors are a class of
drugs that inhibit the enzyme poly (ADP-ribose)
polymerase (PARP), which plays a key role in DNA
repair. These inhibitors are primarily used for
the treatment of cancers that have defects in
DNA repair, such as BRCA-mutated ovarian and
breast cancers. The market for PARP inhibitors
is driven by the increasing demand for targeted
therapies in cancer treatment. Targeted
therapies offer specificity by targeting specific
molecular pathways involved in cancer growth and
progression. PARP inhibitors target the DNA
repair pathway, which is crucial for cancer cell
survival. These inhibitors prevent the repair of
DNA damage, leading to cell death and tumor
shrinkage. Furthermore, the rising incidence of
cancer worldwide is also fueling the demand for
PARP inhibitors. According to the World Health
Organization (WHO), cancer is the second leading
cause of death globally, and accounted for an
estimated 9.6 million deaths in 2018. The high
prevalence and mortality associated with cancer
have led to increased research and development
activities in the field of oncology, driving the
market for PARP inhibitors. Market Dynamics
Driver 1 Increasing demand for targeted
therapies Targeted therapies offer advantages
over conventional chemotherapy by specifically
targeting cancer cells, leading to better
treatment outcomes and reduced side effects. PARP
inhibitors are a promising class of targeted
therapies that have shown significant efficacy in
the treatment of various cancers, especially
those with BRCA mutations. For example, Lynparza
(olaparib), developed by AstraZeneca Plc. and
Merck KGaA, is FDA-approved for the treatment of
ovarian, fallopian tube, and primary peritoneal
cancers in patients with BRCA mutations. The
increasing demand for targeted therapies in
cancer treatment is driving the market for PARP
inhibitors. Driver 2 Rising incidence of cancer
The global burden of cancer is increasing at an
alarming rate. According to the International
Agency for Research on Cancer (IARC), there were
an estimated 18.1 million new cancer cases in
2018. The rising incidence of cancer is
attributed to various factors such as aging
population, lifestyle changes, environmental
factors, and genetic predisposition. PARP
inhibitors have shown promising results in the
treatment of various cancers, including ovarian
and breast cancers. As the incidence of cancer
continues to rise, the demand for effective
treatments such as PARP inhibitors is expected
to increase. SWOT Analysis Strengths
2
1. Targeted therapy for specific molecular
pathways 2. Efficacy in the treatment of cancers
with DNA repair defects Weaknesses 1. High
treatment costs 2. Development of resistance
Opportunities 1. Expansion of application in
other cancer types 2. Increasing research and
development activities Threats 1. Stringent
regulatory requirements 2. Competition from
other targeted therapies Key Takeaways - The
global PARP inhibitor market is expected to
witness high growth, exhibiting a CAGR of 32.4
over the forecast period, due to increasing
demand for targeted therapies and rising
incidence of cancer. - North America is expected
to dominate the market due to the presence of key
players and high adoption of advanced cancer
treatments. - Key players operating in the
global PARP inhibitor market include AstraZeneca
Plc., Johnson Johnson, GlaxoSmithKline plc.,
Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc.,
Bristol - Myers Squibb, Merck KGaA, Genentech,
Inc., Repare Therapeutics Inc., Sierra Oncology,
Inc., Karyopharm Therapeutics Inc., Ono
Pharmaceutical Co., LTD., and Jiangsu Hengrui
Medicine Co., Ltd. These players are focusing on
strategic collaborations, acquisitions, and
product launches to strengthen their market
position. In conclusion, the global PARP
inhibitor market is witnessing significant growth
due to the increasing demand for targeted
therapies and the rising incidence of cancer.
These inhibitors offer promising treatment
options for various cancers, especially those
with DNA repair defects. However, challenges such
as high treatment costs and the development of
resistance need to be addressed for the
widespread adoption of PARP inhibitors in cancer
treatment.